In the latest attempt to examine financial ties between physicians and drug makers, a new study finds that oncologists who received payments for meals, travel, and consulting were more likely to prescribe medicines sold by the companies who provided the largesse.

Specifically, the odds were 78 percent greater that oncologists would prescribe certain brand-name drugs for treating renal cell carcinoma if they had received some type of payment from one of the manufacturers. And the odds were 29 percent higher they would prescribe certain brand-name medicines for treating chronic myeloid leukemia if they had received a payment.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Sounds like junk science to me. The causality could just as easily be going in the other direction: Experienced physicians who prescribed a certain therapy are more likely to receive honoraria from a pharma company to talk with peers. Also, oncologists earn $400K+…but $500 can make them change their clinical judgement? Seriously, STAT should have higher standards.

    See also: https://xkcd.com/552/

    • Hi Adam,
      Fair point. I agree the average payment was small, although the percentages indicating prescribing patterns are interesting. In any event, the researchers acknowledge more work should be done. They call it a proof of principle study, fwiw.
      Regards,
      ed

Your daily dose of news in health and medicine

Privacy Policy